시장보고서
상품코드
1966138

피임약 시장 규모, 점유율, 동향 및 성장 분석 보고서(2026-2034년)

Global Contraceptive Market Size, Share, Trends & Growth Analysis Report 2026-2034

발행일: | 리서치사: Value Market Research | 페이지 정보: 영문 149 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    




※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

피임약 시장 규모는 2025년 297억 1,000만 달러에서 2026년부터 2034년까지 CAGR 6.69%로 성장하여 2034년에는 532억 2,000만 달러에 달할 것으로 예측됩니다.

세계 피임 시장은 가족계획에 대한 인식의 증가, 생식건강에 대한 노력, 정부 지원 인구 억제 프로그램 등으로 인해 꾸준히 성장하고 있습니다. 경구피임약, 콘돔, 자궁내피임기구(IUD), 주사제, 임플란트 등의 제품은 선진국과 신흥시장에서 널리 사용되고 있습니다. 성교육 확대와 의료 서비스 접근성 개선으로 성교육이 더욱 확산되고 있습니다.

주요 성장 요인으로는 여성의 노동력 참여율 증가, 출산 연령의 증가, 공중 보건 정책의 지원 등을 들 수 있습니다. 장기 지속형 가역적 피임법(LARCs)의 기술 발전과 안전성 프로파일의 개선으로 소비자의 신뢰가 높아지고 있습니다. 또한, E-Commerce 플랫폼과 원격의료 상담을 통해 제품의 가용성과 프라이버시 보호가 향상되고 있습니다.

비호르몬 및 남성용 피임법의 지속적인 개발로 향후 전망은 밝으며, 비호르몬 및 남성용 피임법의 지속적인 개발이 진행되고 있습니다. 신흥 지역의 생식 권리에 대한 인식 확대와 헬스케어 자금의 확대는 더 많은 성장을 뒷받침할 것입니다. 그러나 규제적, 문화적, 윤리적 고려사항이 특정 국가의 시장 역학에 영향을 미칠 수 있습니다. 전반적으로 효과적이고 편리한 피임법에 대한 지속적인 수요가 장기적인 성장의 기반이 되고 있습니다.

목차

제1장 소개

제2장 주요 요약

제3장 시장 변수, 동향, 프레임워크

제4장 세계의 피임약 시장 : 제품별

제5장 세계의 피임약 시장 : 연령층별

제6장 세계의 피임약 시장 : 유통 채널별

제7장 세계의 피임약 시장 : 지역별

제8장 경쟁 구도

제9장 기업 개요

KSM 26.03.24

The Contraceptive Market size is expected to reach USD 53.22 Billion in 2034 from USD 29.71 Billion (2025) growing at a CAGR of 6.69% during 2026-2034.

The global contraceptive market has grown steadily due to increasing awareness of family planning, reproductive health initiatives, and government-supported population control programs. Products such as oral contraceptives, condoms, intrauterine devices (IUDs), injectables, and implants are widely used across developed and emerging markets. Expansion of sexual health education and improved access to healthcare services have further driven adoption.

Major growth drivers include rising female workforce participation, delayed parenthood trends, and supportive public health policies. Technological advancements in long-acting reversible contraceptives (LARCs) and improved safety profiles have increased consumer confidence. E-commerce platforms and telehealth consultations have also enhanced product accessibility and privacy.

Future prospects are strong, with continued innovation in non-hormonal and male contraceptive options under development. Expansion of reproductive rights awareness and healthcare funding in emerging regions will likely support further growth. However, regulatory, cultural, and ethical considerations may influence market dynamics in certain countries. Overall, sustained demand for effective and convenient birth control methods underpins positive long-term expansion.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Product

  • Devices
  • Condoms (Male, Female)
  • Intra-Uterine Devices (Hormonal Iud, Copper Iud)
  • Vaginal Rings
  • Subdermal Implants
  • Diaphragms
  • Contraceptive Sponges
  • Drugs
  • Oral Contraceptive Pills
  • Injectable Contraceptives
  • Topical Contraceptives

By Age Group

  • 15 - 44 Years
  • Above 44 Years

By Distribution Channels

  • Retail Pharmacies
  • Hospital Pharmacies
  • Online Channels
  • Other Distribution Channels

COMPANIES PROFILED

  • Afaxys Inc, Agile Therapeutics, Amneal Pharmaceuticals, Bayer AG, Church Dwight Co Inc, Cooper Companies, Evofem Biosciences, HRA Pharma, Maxwellia Ltd, Mayer Laboratories Inc, Mithra Pharmaceuticals, Organon Co

We can customise the report as per your requriements

TABLE OF CONTENTS

Chapter 1. PREFACE

  • 1.1. Market Segmentation & Scope
  • 1.2. Market Definition
  • 1.3. Information Procurement
    • 1.3.1 Information Analysis
    • 1.3.2 Market Formulation & Data Visualization
    • 1.3.3 Data Validation & Publishing
  • 1.4. Research Scope and Assumptions
    • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

  • 2.1. Market Snapshot
  • 2.2. Segmental Outlook
  • 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

  • 3.1. Market Lineage Outlook
  • 3.2. Penetration & Growth Prospect Mapping
  • 3.3. Value Chain Analysis
  • 3.4. Regulatory Framework
    • 3.4.1 Standards & Compliance
    • 3.4.2 Regulatory Impact Analysis
  • 3.5. Market Dynamics
    • 3.5.1 Market Drivers
    • 3.5.2 Market Restraints
    • 3.5.3 Market Opportunities
    • 3.5.4 Market Challenges
  • 3.6. Porter's Five Forces Analysis
  • 3.7. PESTLE Analysis

Chapter 4. GLOBAL CONTRACEPTIVE MARKET: BY PRODUCT 2022-2034 (USD MN)

  • 4.1. Market Analysis, Insights and Forecast Product
  • 4.2. Devices Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.3. Condoms (Male, Female) Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.4. Intra-Uterine Devices (Hormonal Iud, Copper Iud) Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.5. Vaginal Rings Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.6. Subdermal Implants Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.7. Diaphragms Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.8. Contraceptive Sponges Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.9. Drugs Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.10. Oral Contraceptive Pills Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.11. Injectable Contraceptives Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.12. Topical Contraceptives Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL CONTRACEPTIVE MARKET: BY AGE GROUP 2022-2034 (USD MN)

  • 5.1. Market Analysis, Insights and Forecast Age Group
  • 5.2. 15 - 44 Years Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.3. Above 44 Years Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL CONTRACEPTIVE MARKET: BY DISTRIBUTION CHANNELS 2022-2034 (USD MN)

  • 6.1. Market Analysis, Insights and Forecast Distribution Channels
  • 6.2. Retail Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 6.3. Hospital Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 6.4. Online Channels Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 6.5. Other Distribution Channels Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL CONTRACEPTIVE MARKET: BY REGION 2022-2034(USD MN)

  • 7.1. Regional Outlook
  • 7.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 7.2.1 By Product
    • 7.2.2 By Age Group
    • 7.2.3 By Distribution Channels
    • 7.2.4 United States
    • 7.2.5 Canada
    • 7.2.6 Mexico
  • 7.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 7.3.1 By Product
    • 7.3.2 By Age Group
    • 7.3.3 By Distribution Channels
    • 7.3.4 United Kingdom
    • 7.3.5 France
    • 7.3.6 Germany
    • 7.3.7 Italy
    • 7.3.8 Russia
    • 7.3.9 Rest Of Europe
  • 7.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 7.4.1 By Product
    • 7.4.2 By Age Group
    • 7.4.3 By Distribution Channels
    • 7.4.4 India
    • 7.4.5 Japan
    • 7.4.6 South Korea
    • 7.4.7 Australia
    • 7.4.8 South East Asia
    • 7.4.9 Rest Of Asia Pacific
  • 7.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 7.5.1 By Product
    • 7.5.2 By Age Group
    • 7.5.3 By Distribution Channels
    • 7.5.4 Brazil
    • 7.5.5 Argentina
    • 7.5.6 Peru
    • 7.5.7 Chile
    • 7.5.8 South East Asia
    • 7.5.9 Rest of Latin America
  • 7.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 7.6.1 By Product
    • 7.6.2 By Age Group
    • 7.6.3 By Distribution Channels
    • 7.6.4 Saudi Arabia
    • 7.6.5 UAE
    • 7.6.6 Israel
    • 7.6.7 South Africa
    • 7.6.8 Rest of the Middle East And Africa

Chapter 8. COMPETITIVE LANDSCAPE

  • 8.1. Recent Developments
  • 8.2. Company Categorization
  • 8.3. Supply Chain & Channel Partners (based on availability)
  • 8.4. Market Share & Positioning Analysis (based on availability)
  • 8.5. Vendor Landscape (based on availability)
  • 8.6. Strategy Mapping

Chapter 9. COMPANY PROFILES OF GLOBAL CONTRACEPTIVE INDUSTRY

  • 9.1. Top Companies Market Share Analysis
  • 9.2. Company Profiles
    • 9.2.1 Afaxys Inc
    • 9.2.2 Agile Therapeutics
    • 9.2.3 Amneal Pharmaceuticals
    • 9.2.4 Bayer AG
    • 9.2.5 Church & Dwight Co. Inc
    • 9.2.6 Cooper Companies
    • 9.2.7 Evofem Biosciences
    • 9.2.8 HRA Pharma
    • 9.2.9 Maxwellia Ltd
    • 9.2.10 Mayer Laboratories Inc
    • 9.2.11 Mithra Pharmaceuticals
    • 9.2.12 Organon & Co
샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제